• 1
    Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3 edn. Baltimore, MD: Johns Hopkins University Press, 1999.
  • 2
    Kluwe L, Siebert R, Gesk S et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 2004: 23: 111116.
  • 3
    Bengesser K, Cooper DN, Steinmann K et al. A novel third type of recurrent NF1 microdeletion mediated by nonallelic homologous recombination between LRRC37B-containing low-copy repeats in 17q11.2. Hum Mutat 2010: 31: 742751.
  • 4
    Tonsgard JH, Yelavarthi KK, Cushner S, Short MP, Lindgren V. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997: 73: 8086.
  • 5
    Mautner VF, Kluwe L, Friedrich RE et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet 2010: 47: 623630.
  • 6
    Pasmant E, Sabbagh A, Spurlock G et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010: 31: E1506E1518.
  • 7
    Brannan CI, Perkins AS, Vogel KS et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994: 8: 10191029.
  • 8
    Gitler AD, Zhu Y, Ismat FA et al. Nf1 has an essential role in endothelial cells. Nat Genet 2003: 33: 7579.
  • 9
    Venturin M, Bentivegna A, Moroni R, Larizza L, Riva P. Evidence by expression analysis of candidate genes for congenital heart defects in the NF1 microdeletion interval. Ann Hum Genet 2005: 69: 508516.
  • 10
    Friedman JM, Arbiser J, Epstein JA et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002: 4: 105111.
  • 11
    Lin AE, Birch PH, Korf BR et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet 2000: 95: 108117.
  • 12
    Tedesco MA, Di Salvo G, Natale F et al. The heart in neurofibromatosis type 1: an echocardiographic study. Am Heart J 2002: 143: 883888.
  • 13
    Venturin M, Guarnieri P, Natacci F et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet 2004: 41: 3541.
  • 14
    Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 2000: 9: 3546.
  • 15
    Riva P, Corrado L, Natacci F et al. NF1 microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet 2000: 6: 100109.
  • 16
    Stumpf DA, Alksne JF, Annegers JF. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988: 45: 575578.
  • 17
    Roehl AC, Vogt J, Mussotter T et al. Intrachromosomal mitotic nonallelic homologous recombination is the major molecular mechanism underlying type-2 NF1 deletions. Hum Mutat 2010: 31: 11631173.
  • 18
    Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001: 107: E32.
  • 19
    Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007: 115: 163172.
  • 20
    Warnes CA, Liberthson R, Danielson GK et al. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001: 37: 11701175.
  • 21
    Van de Veire NR, De Backer J, Ascoop AK, Middernacht B, Velghe A, Sutter JD. Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals. Int J Cardiovasc Imaging 2006: 22: 633641.
  • 22
    Helmcke F, Nanda NC, Hsiung MC. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987: 75: 175183.
  • 23
    Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999: 83: 897902.
  • 24
    Frankiewicz L. Rare case of v. Recklinghausen disease with a tumor in the left atrium. Pol Tyg Lek 1973: 28: 411412.
  • 25
    McAllister HA, Fenoglio JJ. Tumors of the cardiovascular system. In: Atlas of tumor pathology, second series. Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1987: 7071.
  • 26
    Fischberg C, Cotting J, Hack I, Laurini RN, Payot M. Double compression oesotracheale fatale vasculaire et neurofibromateuse. Arch Pediatr 1996: 3: 12521257.
  • 27
    Lakkis MM, Epstein JA. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 1998: 125: 43594367.
  • 28
    Lasater EA, Li F, Bessler WK et al. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest 2010: 120: 859870.
  • 29
    Bausch B, Borozdin W, Mautner VF et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007: 92: 27842792.